© AP Pfizer and BioNTech have launched a phase 1 trial for an mRNA-based vaccine that would target both COVID-19 and the influenza virus. According to BioNTech, the vaccine candidate is a combination of Pfizer’s flu vaccine candidate, which is in phase 3 clinical development, and the company’s bivalent omicron-specific coronavirus vaccine dose. The study […]

The post Pfizer Testing Combined COVID, Flu Vaccine  appeared first on The St Kitts Nevis Observer.